QPEX BIOPHARMA is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.

Qpex management has a record of deep expertise in the discovery, development, and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance.

The Unmet Need

Untreatable infections due to antimicrobial drug resistance negates many advances in medical technology

 

The year 2019 marks the 50th anniversary of the publication of the landmark science fiction novel The Andromeda Strain (Michael Crichton).  The story describes the fictitious account of a highly mutable micro-organism that infects and kills humans, escapes containment, and threatens mankind. 

The story behind the Andromeda Strain makes for great novels and films on the horrors of a battle between man and unseen micro-organisms. In our “real world”, we are now challenged by antimicrobial drug resistance (also known as AMR), common bacterial pathogens no longer are treatable by antibiotic drugs.  Infections that were once considered mild  and easily treated can become life threatening in the absence of active antibiotics.  

 

AMR results in a world where the advances in modern medicine are lost...

Our Approach

DEFINE

drug resistance mechanisms

 

IMPROVE

existing proven classes of drugs

FIND

new chemical classes of drugs that overcome drug resistance

Reversing antibiotic resistance

Making antibiotics work better

We have important partnerships and we communicate the optimal use of our products

COLLABORATE

DISCOVERY

ENZYME INHIBITION

COMBINE